Table 3. A comparison between SOCS3 methylation status and the clinical features of NSCLC patients.
| Variables | SOCS3 gene hypermethylation (n=184) | SOCS3 gene unmethylation (n=216) | P |
|---|---|---|---|
| Age (years), n | 0.532 | ||
| ≥55 | 85 | 100 | |
| <55 | 99 | 116 | |
| Sex, n | 0.038 | ||
| Male | 87 | 82 | |
| Female | 97 | 134 | |
| Smoker, n | 0.461 | ||
| Non-smoker | 55 | 77 | |
| Ever smoker | 63 | 70 | |
| Current smoker | 66 | 69 | |
| TNM stage, n | 0.112 | ||
| IIIB | 87 | 97 | |
| IV | 88 | 128 | |
| Differentiation, n | 0.038 | ||
| Low | 79 | 73 | |
| High | 105 | 143 | |
| Treatment response, n | <0.001 | ||
| Good | 59 | 125 | |
| Poor | 125 | 111 | |
SOCS3, suppressor of cytokine signaling 3; NSCLC, non-small cell lung cancer; TNM, tumor-node-metastases.